BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 16014854)

  • 1. Response of Plasmodium falciparum to cotrimoxazole therapy: relationship with plasma drug concentrations and dihydrofolate reductase and dihydropteroate synthase genotypes.
    Khalil IF; Rønn AM; Alifrangis M; Gabar HA; Jelinek T; Satti GM; Bygbjerg IC
    Am J Trop Med Hyg; 2005 Jul; 73(1):174-7. PubMed ID: 16014854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms in Plasmodium falciparum dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria.
    Happi CT; Gbotosho GO; Folarin OA; Akinboye DO; Yusuf BO; Ebong OO; Sowunmi A; Kyle DE; Milhous W; Wirth DF; Oduola AM
    Acta Trop; 2005 Sep; 95(3):183-93. PubMed ID: 16023986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular epidemiology of malaria in Cameroon. XXVII. Clinical and parasitological response to sulfadoxine-pyrimethamine treatment and Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase alleles in Cameroonian children.
    Tahar R; Basco LK
    Acta Trop; 2007 Aug; 103(2):81-9. PubMed ID: 17640607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana.
    Mockenhaupt FP; Teun Bousema J; Eggelte TA; Schreiber J; Ehrhardt S; Wassilew N; Otchwemah RN; Sauerwein RW; Bienzle U
    Trop Med Int Health; 2005 Sep; 10(9):901-8. PubMed ID: 16135198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic efficacy of sulfadoxine-pyrimethamine and prevalence of resistance markers in Tanzania prior to revision of malaria treatment policy: Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase mutations in monitoring in vivo resistance.
    Mugittu K; Ndejembi M; Malisa A; Lemnge M; Premji Z; Mwita A; Nkya W; Kataraihya J; Abdulla S; Beck HP; Mshinda H
    Am J Trop Med Hyg; 2004 Dec; 71(6):696-702. PubMed ID: 15642957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of antifolate resistance in vitro and point mutations in dihydrofolate reductase and dihydropteroate synthetase genes of Plasmodium falciparum.
    Biswas S
    J Postgrad Med; 2004; 50(1):17-20. PubMed ID: 15047993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The implication of dihydrofolate reductase and dihydropteroate synthetase gene mutations in modification of Plasmodium falciparum characteristics.
    A-Elbasit IE; Alifrangis M; Khalil IF; Bygbjerg IC; Masuadi EM; Elbashir MI; Giha HA
    Malar J; 2007 Aug; 6():108. PubMed ID: 17686173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutations in the dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum and resistance to sulfadoxine-pyrimethamine in Sri Lanka.
    Hapuarachchi HC; Dayanath MY; Bandara KB; Abeysundara S; Abeyewickreme W; de Silva NR; Hunt SY; Sibley CH
    Am J Trop Med Hyg; 2006 Feb; 74(2):198-204. PubMed ID: 16474070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria.
    Basco LK; Tahar R; Keundjian A; Ringwald P
    J Infect Dis; 2000 Aug; 182(2):624-8. PubMed ID: 10915101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two mutations in dihydrofolate reductase combined with one in the dihydropteroate synthase gene predict sulphadoxine-pyrimethamine parasitological failure in Ugandan children with uncomplicated falciparum malaria.
    Talisuna AO; Nalunkuma-Kazibwe A; Langi P; Mutabingwa TK; Watkins WW; Van Marck E; Egwang TG; D'Alessandro U
    Infect Genet Evol; 2004 Dec; 4(4):321-7. PubMed ID: 15374529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrimethamine/sulfadoxine combination in the treatment of uncomplicated falciparum malaria: relation between dihydropteroate synthase/dihydrofolate reductase genotypes, sulfadoxine plasma levels, and treatment outcome.
    Khalil I; Alifrangis M; Rønn AM; Gabar HA; Jelinek T; Satti GM; Bygbjerg IC
    Am J Trop Med Hyg; 2002 Sep; 67(3):225-9. PubMed ID: 12408659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with in vitro resistance of Plasmodium falciparum to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole.
    Khalil I; Rønn AM; Alifrangis M; Gabar HA; Satti GM; Bygbjerg IC
    Am J Trop Med Hyg; 2003 May; 68(5):586-9. PubMed ID: 12812351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance and genetic diversity of Plasmodium falciparum parasites from suriname.
    Peek R; VAN Gool T; Panchoe D; Greve S; Bus E; Resida L
    Am J Trop Med Hyg; 2005 Nov; 73(5):833-8. PubMed ID: 16282289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Artesunate-dapsone-proguanil treatment of falciparum malaria: genotypic determinants of therapeutic response.
    Krudsood S; Imwong M; Wilairatana P; Pukrittayakamee S; Nonprasert A; Snounou G; White NJ; Looareesuwan S
    Trans R Soc Trop Med Hyg; 2005 Feb; 99(2):142-9. PubMed ID: 15607340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cotrimoxazole prophylaxis taken by human immunodeficiency virus (HIV)-infected persons on the selection of sulfadoxine-pyrimethamine-resistant malaria parasites among HIV-uninfected household members.
    Malamba SS; Mermin J; Reingold A; Lule JR; Downing R; Ransom R; Kigozi A; Hunt BM; Hubbard A; Rosenthal PJ; Dorsey G
    Am J Trop Med Hyg; 2006 Sep; 75(3):375-80. PubMed ID: 16968909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct haplotypes of dhfr and dhps among Plasmodium falciparum isolates in an area of high level of sulfadoxine-pyrimethamine (SP) resistance in eastern Sudan.
    Al-Saai S; Kheir A; Abdel-Muhsin AM; Al-Ghazali A; Nwakanma D; Swedberg G; Babiker HA
    Infect Genet Evol; 2009 Sep; 9(5):778-83. PubMed ID: 19379843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimalarial resistance and DHFR/DHPS genotypes of Plasmodium falciparum three years after introduction of sulfadoxine-pyrimethamine and amodiaquine in rural Tanzania.
    Eriksen J; Mwankusye S; Mduma S; Veiga MI; Kitua A; Tomson G; Petzold MG; Swedberg G; Gustafsson LL; Warsame M
    Trans R Soc Trop Med Hyg; 2008 Feb; 102(2):137-42. PubMed ID: 18082233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular surveillance of mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum in Ethiopia.
    Gebru-Woldearegai T; Hailu A; Grobusch MP; Kun JF
    Am J Trop Med Hyg; 2005 Dec; 73(6):1131-4. PubMed ID: 16354825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in dhfr in Plasmodium falciparum infections selected by chlorproguanil-dapsone treatment.
    Curtis J; Maxwell CA; Msuya FH; Mkongewa S; Alloueche A; Warhurst DC
    J Infect Dis; 2002 Dec; 186(12):1861-4. PubMed ID: 12447777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use.
    Nsimba B; Jafari-Guemouri S; Malonga DA; Mouata AM; Kiori J; Louya F; Yocka D; Malanda M; Durand R; Le Bras J
    Trop Med Int Health; 2005 Oct; 10(10):1030-7. PubMed ID: 16185238
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.